MedTrace Logo

Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers

NCT03764462 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-08-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-101 in healthy volunteers

Conditions

Interventions

DRUG

AD-101 45mg

Raloxifene 45mg tablet

DRUG

Raloxifene 60mg

Raloxifene 60mg tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon, M.D., Ph.D · Kyungpook National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-14
Primary Completion
2019-01-02
Completion
2019-02-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03764462 on ClinicalTrials.gov